PMI US CORPORATE SERVICES INC. (FKA PMI GLOBAL SERVICES INC.) lobbying for PMI US CORPORATE SERVICES INC. (FKA PMI GLOBAL SERVICES INC.)

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$1,890,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

DAVID SOURS New on this filing

Previously held: Sr. Advsr Rep. Carter (1/25 - 4/25). COS Rep. Ferguson (6/19 - 1/25); Rep. Hice (1/15 - 6/19); and Rep. Gingrey (2/09 - 12/14). Staff Assistant/Leg Assistant/Leg Director for Phil Gingrey (1/05 - 1/09)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 10

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
State, Dept of (DOS)
Treasury, Dept of
U.S. Trade Representative (USTR)
Veterans Affairs, Dept of (VA)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Lobbying activity 8

Defense

Discussions related to tobacco harm reduction pilot programs on military installations.

Taxation/Internal Revenue Code

Discussions related to the federal excise tax on ethanol and its application to manufacturing of tobacco products.

Budget/Appropriations

S.______/H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; provisions related to reform of FDA.

Foreign Relations

Discussions related to U.S. policy guidance provided to executive branch personnel regarding foreign government engagements.

Health Issues

Discussions related to costs incurred by Medicare & Medicaid for treatment of smoking related diseases; public impact of smoking related diseases and the potential cost savings and improved public health outcomes related to tobacco harm reduction programs and products.

Tobacco

Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to the importance of tobacco harm reduction and the availability of FDA-authorized smoke-free products. Discussions related to enforcement of illicit tobacco products, including importation and distribution of counterfeit products. Discussions related to user fees for tobacco product and nicotine products. Discussions related to efforts to prevent underage access to tobacco products. Discussions related to reforms of the Food and Drug Administrations Center for Tobacco Products. Discussions related to PMTA and MRTPA submissions and FDA authorization of scientifically-substantiated products. Discussions related to the misperception of nicotine in the context of tobacco policy and public health.

Trade (domestic/foreign)

Discussions related to potential tariffs on imported products.

Veterans

Discussions related to Veterans and health related issues.

Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

PHILIP MORRIS PRODUCTS S.A. (PARENT COMPANY IS PMI)

Switzerland · Neuchatel · owns 0% of the client · contributed $200,000.00